[Table/Fig-6]:
Comparative Studies
| Antimicrobial | Our Study | Neelam et al.,., (Chandigarh) [1] | Dash M et al., ., (Odisha) [17] | Goel N et al.,., (Haryana) [18] | Tripathi et al.,., (Bhopal) [19] | Rit K et al.,., (kolkata) [20] |
|---|---|---|---|---|---|---|
| Resistance % | Resistance% | Resistance% | Resistance% | Resistance% | Resistance% | |
| Cip | 75.64 | 26.8 | 86 | 89.7 | ND | ND |
| G | 82.72 | 20.1 | 70 | ND | ND | 70.3 |
| Cefo | 80.54 | 22.3 | 93 | 100 | 100 | 74.1 |
| Ak | 88.95 | 25.4 | 61 | 87.2 | 55 | 14.29 |
| Imp | 15.21 | 67.4 | 19 | 25.6 | 43 | 5.2 |
| PT | 32.97 | 61.6 | 23 | ND | 86.92 | 18,2 |
Cip:Ciprofloxacin G:Gentamicin Cefo:Cefotaxime
Ak:Amikacin Imp:Imipenem PT:Piperacillin –Tazobactam ND: Not done